View in EDS

Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.

Saved in:
Bibliographic Details
Title: Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.
Authors: Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. GCIssa@mdanderson.org., Larson RA; University of Chicago, Chicago, IL., Hughes TP; South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA., Hochhaus A; Hematology and Medical Oncology, Universitätsklinikum Jena, Jena., Takahashi N; Department of Hematology, Akita University, Akita City., Bombaci F; CML Patients Group, CML Advocates Network, Turin., Wang J; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin., Kim DW; Ujieongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si., Kim DDH; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON., Mayer J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czech Republic., Goh YT; Department of Hematology, Singapore General Hospital., Le Coutre P; Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin., Kim I; Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul., Etienne G; Hematology Department, Institut Bergonié, Bordeaux., Andorsky D; Sarah Cannon Research Institute at Rocky Mountain Cancer Centers, Boulder, CO., Gu E; Novartis Pharmaceuticals Corporation, Cambridge, MA., Zhang Y; Novartis Pharmaceuticals Corporation, East Hanover, NJ., McCulloch T; Novartis Pharmaceuticals Corporation, Basel., Agrawal N; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Jinwal R; Novartis Healthcare Pvt. Ltd, Hyderabad., Damon A; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Sadek I; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Cortes JE; Georgia Cancer Center, Augusta University, Augusta, GA.
Source: Haematologica [Haematologica] 2026 Jul 02. Date of Electronic Publication: 2026 Jul 02.
Publication Type: Journal Article
Journal Info: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42389818
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Issa+GC%22">Issa GC</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. GCIssa@mdanderson.org.<br /><searchLink fieldCode="AU" term="%22Larson+RA%22">Larson RA</searchLink>; University of Chicago, Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Hughes+TP%22">Hughes TP</searchLink>; South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA.<br /><searchLink fieldCode="AU" term="%22Hochhaus+A%22">Hochhaus A</searchLink>; Hematology and Medical Oncology, Universitätsklinikum Jena, Jena.<br /><searchLink fieldCode="AU" term="%22Takahashi+N%22">Takahashi N</searchLink>; Department of Hematology, Akita University, Akita City.<br /><searchLink fieldCode="AU" term="%22Bombaci+F%22">Bombaci F</searchLink>; CML Patients Group, CML Advocates Network, Turin.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin.<br /><searchLink fieldCode="AU" term="%22Kim+DW%22">Kim DW</searchLink>; Ujieongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si.<br /><searchLink fieldCode="AU" term="%22Kim+DDH%22">Kim DDH</searchLink>; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON.<br /><searchLink fieldCode="AU" term="%22Mayer+J%22">Mayer J</searchLink>; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Masaryk University, Brno, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Goh+YT%22">Goh YT</searchLink>; Department of Hematology, Singapore General Hospital.<br /><searchLink fieldCode="AU" term="%22Le+Coutre+P%22">Le Coutre P</searchLink>; Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin.<br /><searchLink fieldCode="AU" term="%22Kim+I%22">Kim I</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul.<br /><searchLink fieldCode="AU" term="%22Etienne+G%22">Etienne G</searchLink>; Hematology Department, Institut Bergonié, Bordeaux.<br /><searchLink fieldCode="AU" term="%22Andorsky+D%22">Andorsky D</searchLink>; Sarah Cannon Research Institute at Rocky Mountain Cancer Centers, Boulder, CO.<br /><searchLink fieldCode="AU" term="%22Gu+E%22">Gu E</searchLink>; Novartis Pharmaceuticals Corporation, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Zhang+Y%22">Zhang Y</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ.<br /><searchLink fieldCode="AU" term="%22McCulloch+T%22">McCulloch T</searchLink>; Novartis Pharmaceuticals Corporation, Basel.<br /><searchLink fieldCode="AU" term="%22Agrawal+N%22">Agrawal N</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ.<br /><searchLink fieldCode="AU" term="%22Jinwal+R%22">Jinwal R</searchLink>; Novartis Healthcare Pvt. Ltd, Hyderabad.<br /><searchLink fieldCode="AU" term="%22Damon+A%22">Damon A</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ.<br /><searchLink fieldCode="AU" term="%22Sadek+I%22">Sadek I</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ.<br /><searchLink fieldCode="AU" term="%22Cortes+JE%22">Cortes JE</searchLink>; Georgia Cancer Center, Augusta University, Augusta, GA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220417435%22">Haematologica</searchLink> [Haematologica] 2026 Jul 02. <i>Date of Electronic Publication: </i>2026 Jul 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Ferrata+Storti+Foundation%22">Ferrata Storti Foundation </searchLink><i>Country of Publication: </i>Italy <i>NLM ID: </i>0417435 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1592-8721 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203906078%22">03906078 </searchLink><i>NLM ISO Abbreviation: </i>Haematologica <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42389818
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3324/haematol.2025.300145
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Issa GC
      – PersonEntity:
          Name:
            NameFull: Larson RA
      – PersonEntity:
          Name:
            NameFull: Hughes TP
      – PersonEntity:
          Name:
            NameFull: Hochhaus A
      – PersonEntity:
          Name:
            NameFull: Takahashi N
      – PersonEntity:
          Name:
            NameFull: Bombaci F
      – PersonEntity:
          Name:
            NameFull: Wang J
      – PersonEntity:
          Name:
            NameFull: Kim DW
      – PersonEntity:
          Name:
            NameFull: Kim DDH
      – PersonEntity:
          Name:
            NameFull: Mayer J
      – PersonEntity:
          Name:
            NameFull: Goh YT
      – PersonEntity:
          Name:
            NameFull: Le Coutre P
      – PersonEntity:
          Name:
            NameFull: Kim I
      – PersonEntity:
          Name:
            NameFull: Etienne G
      – PersonEntity:
          Name:
            NameFull: Andorsky D
      – PersonEntity:
          Name:
            NameFull: Gu E
      – PersonEntity:
          Name:
            NameFull: Zhang Y
      – PersonEntity:
          Name:
            NameFull: McCulloch T
      – PersonEntity:
          Name:
            NameFull: Agrawal N
      – PersonEntity:
          Name:
            NameFull: Jinwal R
      – PersonEntity:
          Name:
            NameFull: Damon A
      – PersonEntity:
          Name:
            NameFull: Sadek I
      – PersonEntity:
          Name:
            NameFull: Cortes JE
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 07
              Text: 2026 Jul 02
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1592-8721
          Titles:
            – TitleFull: Haematologica
              Type: main
ResultId 1